NetworkNewsBreaks – Brain Scientific Inc. (BRSF)
Post# of 129
(Total Views: 182)
Posted On: 07/08/2021 3:10:24 PM
NetworkNewsBreaks – Brain Scientific Inc. (BRSF) Brings Cutting-Edge Tech to the Neurology Market
Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has developed cutting-edge tech that bridges the widening gap in access to quality care. The company’s clinical-grade neurological devices, NeuroCap(TM) and NeuroEEG(TM), are portable, cost-efficient, easy-to-use, and allow for long-term monitoring. This technology will be part of a ketamine clinical study conducted by Ehave Inc. (OTC: EHVVF) to establish the statistical correlation between ketamine treatment and patient improvement. “Using BRSF’s technology, Ehave will be able to brain map the volunteer patients and show changes in the neuroplasticity of the areas impacted,” reads a recent article. “BRSF’s technology is ideal for clinical studies because of the company’s AI-assisted diagnostic analysis that increases the efficiency, consistency and accuracy of the data collected. Ehave is the newest to join the quickly expanding list of clinical studies that have taken advantage of BRSF’s next-generation technological solutions for the neurology market.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has developed cutting-edge tech that bridges the widening gap in access to quality care. The company’s clinical-grade neurological devices, NeuroCap(TM) and NeuroEEG(TM), are portable, cost-efficient, easy-to-use, and allow for long-term monitoring. This technology will be part of a ketamine clinical study conducted by Ehave Inc. (OTC: EHVVF) to establish the statistical correlation between ketamine treatment and patient improvement. “Using BRSF’s technology, Ehave will be able to brain map the volunteer patients and show changes in the neuroplasticity of the areas impacted,” reads a recent article. “BRSF’s technology is ideal for clinical studies because of the company’s AI-assisted diagnostic analysis that increases the efficiency, consistency and accuracy of the data collected. Ehave is the newest to join the quickly expanding list of clinical studies that have taken advantage of BRSF’s next-generation technological solutions for the neurology market.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)